Definium Therapeutics, Inc. filed a Form 8-K with the SEC on September 14, 2026, disclosing positive topline data from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder, along with an accompanying investor presentation posted to the company's website.

Key Highlights

  • Phase 3 data announced: Definium Therapeutics reported positive topline data from the Panorama study of DT120 ODT for generalized anxiety disorder.
  • Press release issued: A press release announcing the topline data was issued on September 14, 2026, and attached as Exhibit 99.1.
  • Presentation published: A Panorama topline data presentation was posted to the company's website on September 14, 2026, and attached as Exhibit 99.2.
  • Emerging growth company: The registrant confirmed its status as an emerging growth company under applicable SEC rules.
  • Signed by CEO: The filing was signed by Robert Barrow, Chief Executive Officer of Definium Therapeutics, Inc.

Definium Therapeutics Discloses Panorama Phase 3 Results for DT120 ODT

Definium Therapeutics, Inc. (NASDAQ:DFTX), incorporated in British Columbia and headquartered at One World Trade Center, Suite 8500, New York, New York 10007, filed a current report on September 14, 2026. Under Item 7.01 (Regulation FD Disclosure), the company disclosed that it issued a press release on that date announcing what the filing describes as "positive topline data" from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder.

Under Item 8.01 (Other Events), the filing further states that the company posted a presentation discussing the Panorama topline data to its website on the same date. Both the press release and the presentation are incorporated by reference into their respective items and attached as exhibits to the filing. The filing notes that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not subject to the liabilities of that section.

The filing was signed by Robert Barrow in his capacity as Chief Executive Officer. Definium Therapeutics indicated it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and has not elected to use the extended transition period for new or revised financial accounting standards.

What Was Disclosed

Definium Therapeutics filed an 8-K on September 14, 2026, reporting positive Phase 3 Panorama topline data for DT120 ODT in generalized anxiety disorder, with a press release and a data presentation both attached as exhibits.